BOSTON, Massachusetts, June 14 [Category: BizHospital] -- The Dana-Farber Cancer Institute issued the following news release: * * * Fixed-Duration Triplet Therapy Demonstrates Efficacy for Patients with Relapsed/Refractory CLL * A Dana-Farber Cancer Institute investigator presented positive interim data from the BRUIN CLL-322 trial, the first randomized phase 3 data to be reported about a Bruton tyrosine kinase (BTK) inhibitor as part of a fixed-duration therapy in relapsed/refractory chroni  more

BOSTON, Massachusetts, June 11 -- The Massachusetts Department of Elementary and Secondary Education posted the following news release: * * * Healey-Driscoll Administration Hosts Statewide Civics Project Showcases 1,150 students from 80 districts participated in events in Boston, Dartmouth, Springfield and Worcester - EVERETT - The Healey-Driscoll Administration hosted four Massachusetts Civics Project Showcases in collaboration with Generation Citizen between May 26 and June 5 in Springfie  more

BOSTON, Massachusetts, June 14 [Category: BizHospital] -- The Dana-Farber Cancer Institute issued the following news release: * * * ImmunoPRISM Trial Shows Teclistamab Improves Depth of Response and Progression-Free Survival in High-Risk Smoldering Multiple Myeloma * Dana-Farber Cancer Institute investigators presented encouraging positive results from the phase 2 ImmunoPRISM trial, a first-of-its-kind randomized trial of teclistamab, a BCMA-targeted bispecific antibody, in high-risk smolder  more